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Genetic counselling and genetic testing of breast cancer patients can be helpful in estimating 
recurrence risks and guiding clinical management. Genetic testing results are useful for family 
members and their medical decisions as well. However, not all breast cancer patients are eligible 
for genetic counselling, but must meet eligibility criteria in Ontario to be referred. We studied 
two groups of patients – male breast cancer patients and young female patients aged 35 or under 
– who make up of a small subset of overall breast cancer patients. These groups should be 
offered genetic testing irrespective of family history. They could also potentially represent 
unique genetic profiles, different from the majority of breast cancer patients. Our study showed 
that the genetic testing uptake rates were 44% for male patients and 60% for young female 
patients, respectively. Pathogenic mutation rates were 4% for male patients and 25% for young 
patients, respectively. Our study demonstrated that 1) genetic referral rates and testing rates are 
low, and 2) pathogenic mutation rates are different from the general breast cancer population.  
 
Introduction 
Breast cancer is one of the most common cancers occurring in Canadians, with approximately 1 
in 8 Canadian women affected during her lifetime (Canadian Cancer Stats, 2012). The majority 
of breast cancer is diagnosed in women over 50 years of age while 7% of breast cancer is 
diagnosed among women age 40 years and younger (Brenner et al., 2016). While uncommon, 
breast cancer can also occur in males. It is estimated that <1% of breast cancer occurs in men 
(Rizzolo et al., 2013). Not surprisingly, research most often focuses on older female populations, 
and breast cancer in males and young females is not routinely examined due to smaller sample 
sizes (Brenner et al., 2016; Rizzolo et al., 2013). Currently, treatment strategies for these 
individuals are extrapolated from older female patients, which may result in suboptimal 
outcomes.  
 
Clinical outcomes such as risks of contralateral breast cancer, local and distant recurrence, and 
subsequent mortality are worse among young women with breast cancer than older women 
(Brenner et al., 2016). Routine breast screening begins at age 50 in Ontario, contributing to 
delayed discovery and more advanced stage of cancer in women affected prior to this age. In 
terms of tumor pathology, distinct subtypes are more prevalent in younger patients than among 
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older women, including triple-negative breast cancer (TNBC), TP53-positive, and HER-2 over-
expressing tumors (Brenner et al., 2016). All these factors lead to worse outcomes for the 
patients. Despite these known differences in breast cancer outcomes and tumor subtypes, there is 
a limited understanding of genetic etiology, epidemiology, and optimal therapeutic strategies for 
breast cancer in young women.  
 
Similarly, clinical outcomes of male breast cancer (MBC) tend to be poor due to lack of breast 
screening guidelines in men; because of this, tumors tend to be at more advanced stages once 
discovered. There have been some efforts to study MBC; however, due to their rarity, little is 
known. MBC accounts for less than 1% of all breast cancers and less than 1% of all cancers in 
men (Rizzolo et al., 2013). Histologically, the majority of MBCs are invasive ductal carcinomas 
(Fentiman, 2018) and can be classified as luminal A (ER+, PR+, HER2-) (60-98%) (Deb et al., 
2014; Johansson, Killander, Linderholm, & Hedenfalk, 2014). Fewer basal-like (TNBC) (0-2% 
vs. 16%) and HER2-enriched (0% vs. 6%) MBC tumors have been reported compared to female 
breast cancer (Johansson et al., 2014). These data further suggest that men and women diagnosed 
with breast cancer of similar immunohistochemical (IHC)-based subtype do not have similar 
outcomes, demonstrating different responses to standard therapies. Taken together, this indicates 
the need for identification of additional biomarkers to more accurately classify all cases of MBC 
and inform more effective treatment strategies (Johansson et al., 2014).  
 
While a relatively small population of young females are diagnosed with breast cancer, they tend 
to be diagnosed with more advanced stages of cancer, which contributes to a disproportionately 
high rate of mortality. Screening with mammogram and breast MRI annually starts at age 30 for 
those who are considered at high risk for breast cancer based on risk assessment at a genetics 
clinic, rather than starting at age 50 for the general population.  Women are included in the high-
risk group if they are known carriers of pathogenic variant, have first degree relatives with 
pathogenic variant, have been assessed to be at a greater than 25% lifetime risk using an 
established risk assessment tool at a genetics clinic, or have received chest radiation treatment 
before age 30 and at least 8 years previously.  
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Majority of breast cancers occur sporadically, but approximately 10% are hereditary. Being a 
carrier of a pathogenic variant of certain genes, such as BRCA1/2, PALB2, PTEN, STK11, TP53, 
ATM, BARD1, CHEK2, NF1, RAD50, RAD51C, RAD51D among others, increase one’s risk of 
developing breast cancer significantly.  
 
Studies have shown that breast cancer in younger women has as distinctive profile in terms of 
risk factors, clinical outcomes, and tumor biology (Rizzolo et al., 2013). There is a lack of 
understanding about the genetic profiles of young females with breast cancer, suggesting that the 
existing literature does not reflect the insights afforded by genetic testing. Similarly, breast 
cancer in males is also regarded to have a unique disease profile compared to that of older female 
patients. Breast cancer risk for male carrier of mutations in BRCA1/2 appears to be lower 
compared to female carriers (Canadian Cancer Stats). Pathogenic variant carriers of BRCA2 are 
considered to be at an increased risk (5-10%) of developing breast cancer in males (Tai, 
Domchek, Parmigiani, & Chen, 2007). As with the young female population, there is a general 
shortage of current understanding of male breast cancer genetics. With the limited understanding 
of the cancer biology as well as their genetic status, the affected individuals face challenge in 
receiving appropriately tailored treatment and testing plans. A better understanding of the genetic 
and pathologic profiles of breast cancer in these populations would likely improve the quality of 
care and improve outcomes.  
 
Current guidelines for referral to genetic counselling state that any women diagnosed with breast 
cancer at age 35 or under or a male diagnosed with breast cancer at any age should be referred, 
regardless of personal or family history of breast and/or ovarian cancer. Similar guidelines are in 
place for ovarian cancer diagnoses, yet 55% of women who are diagnosed are unaware of the 
availability of genetic testing (reference). A previous study by Demsky et al. (year) looked at the 
referral rates of ovarian cancer cases to genetic counselling, and whether having a family history 
of breast/ovarian cancer influenced the referral (Armel et al., 2013). Only 23% of women with 
invasive serous cancer in Ontario attended genetic counselling services (Armel et al., 2013); of 
those, 99% of women pursued genetic testing.  Of women wound to carry a pathogenic mutation,  
16% had no previous family history (Armel et al., 2013). These data suggest that among some 
cancer patients, it is lack of awareness of the availability of testing – rather than lack of interest 
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in genetic testing – that may act as a significant barrier to genetic counseling. Even with 
demonstrated need for public awareness, education initiatives will be ineffective if physicians 
caring for women with breast cancer are unaware of recommended referral practices. It is critical 
for physicians to be aware of referral guidelines so that they assist patients who are eligible for 
genetic counseling. Presence of family history is a component; however, this should not the only 
criteria alarms a physician. Cases of rarer cancer occurrence like male breast cancer, ovarian 
cancer, or breast cancer in young patients should all lead to genetic counseling services. In a 
study examining referrals for women with ovarian cancer who had a strong family history of 
cancer, it was noted that women were significantly more likely to be referred for genetic 
counselling (Meyer et al., 2010).  
 
The provision of genetic counseling and genetic testing to patients with breast cancer has many 
benefits, foremost among these the potential for the prevention of future cancers in both the 
patient and their biological relatives. High-risk cancer screening protocols and risk-reducing 
strategies for BRCA1 and BRCA2 mutation carriers are well established (Clinical, Guidelines, & 
Guidelines, 2018; Meyer LA, Anderson Me, Lacou Ra, Suri A, Daniels Ms, Urbauer DL, 
Nogueras-Gonzalez GM, Schmeler KM, Gershenson DM, 2010). It has been demonstrated that 
identifying mutation carriers and their families with hereditary predisposition is cost-effective in 
preventing future cancers (Warner, 2018).  In addition to prevention, genetic testing results can 
impact treatment course, including platinum chemotherapy and Poly (ADP)-ribose polymerase 
(PARP) inhibitors, which have shown to have high response rates in patients with recurrent 
disease (Warner, 2018). Given these benefits, guidelines have been published to help physicians 
determine who refer for genetic counseling (Clinical et al., 2018). In 2001, the province of 
Ontario expanded its BRCA1 and BRCA2 genetic testing eligibility criteria to include all men 
diagnosed with breast cancer, irrespective of age or family history, as well as women under age 
35, irrespective of family history. The Familial Breast and Ovarian Cancer Clinic (FBOCC) at 
Princess Margaret Hospital (PMH) is a specialized cancer genetics clinic within one of the 
largest oncology programs in Canada. Evaluating men and young women diagnosed with breast 
cancer at PMH, the number who had clinical genetic counseling at FBOCC, and the number who 
underwent testing through Mount Sinai Hospital (MSH) pathology lab provides an estimate of 
the proportion of male and young female patients who are offered genetic testing. By studying 
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trends at this centre, we can characterize referral practices and identify potential barriers to 




The study protocol received research ethics board approval from University Health Network in 
Toronto. Females aged 35 or younger or males diagnosed with breast cancer (invasive ductal 
carcinoma, adenocarcinoma, carcinoma NOS, invasive mammary, DCIS NOS, ductal carcinoma, 
ductal micropapillary carcinoma, invasive duct and lobular carcinoma, invasive lobular 
carcinoma, intraductal carcinoma, intraductal micropapillary carcinoma, LCIS NOS, lobular 
carcinoma, medullary carcinoma NOS, metaplastic carcinoma NOS, micropapillary carcinoma 
NOS, mucinous adenocarcinoma, papillary carcinoma, and tubular carcinoma) between 2000 and 
end of 2015 at Princess Margaret Hospital (PMH) were identified through the PMH Cancer 
registry. All patients were either diagnosed at PMH, and/or completed their initial treatment at 
PMH. Patients who were seen for consultation only and patients diagnosed with low grade 
malignant potential breast tumours were excluded. All those who presented for genetic 
counselling, the date of their first appointment, and any genetic testing results were identified 
from the Familial Breast and Ovarian Cancer Centre (FBOCC). Family history of cancer was 
extracted from the three-generation pedigree contained in the FBOCC chart.  
 
Statistical analysis 
Descriptive statistics were used to summarize patient demographics. Chi-Square tests and 
univariate analysis were used to examine association between the year of diagnosis and time 
between diagnosis and first visit to the FBOCC. The probability of having genetic counseling 
after a diagnosis of breast cancer was estimated using multivariable logistic regression with age 
and year of diagnosis as explanatory variables. Mutation rates and family history among patients 





Genetic testing included analysis of the BRCA1 and BRCA2, TP53 genes between 2000 and 
2014, and thereafter a panel of 20 genes (ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, 
CHEK2, EPCAM, FANCC, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, PTEN, RAD51C, 
RAD51D, TP53, XRCC2). DNA was isolated from patients’ peripheral blood lymphocytes and 
testing was performed using different technology, including protein truncation test (PTT), 
denaturing high performance liquid chromatography (DHPLC), sequencing and multiplex 
ligation-dependent probe amplification (MPLA).  
 
Male breast cancer population 
A total of 101 eligible patients were identified from the PMH cancer registry; 28 received 
genetic counseling at FBOCC and 16 received genetic counseling elsewhere; 44 were tested 
through Mount Sinai Pathology Lab (Fig 1). Mean age at the time of diagnosis was 63.4 years 
(range); there was not a statistically significant difference in mean age among those who had 
genetic counseling (60.5 years, range 53-85) and those who did not have genetic counseling 
(65.6 years, range 39-88) (p=0.195) (Table 6). Of men seen for genetic counseling, 14/26 (54%) 
reported a positive family history of breast cancer and 18/26 (69%) reported family history of 
any cance. Family history information could not be obtained for the 16 patients who were not 
seen for genetic counseling at FBOCC. In total, 26 of 28 (89.3%) men who had genetic 
counseling at FBOCC pursued genetic testing. Two of the 44 (4.5%) men who underwent genetic 
testing were found to have a BRCA1 or BRCA2 mutation (Table 1). The patient with BRCA1 
pathogenic mutation did not have a family history of breast or ovarian cancer, though there was 
family history of another cancer (type not specified). Family history information on the patient 
with BRCA2 mutation was not available as he was seen elsewhere for genetic counselling.  
 
Univariate analysis results showed that the number of men seen for genetic counseling did not 
increase over time (Table 4, Fig5b), and age at diagnosis was not a significant predictor of 
attendance at genetic counseling or testing (p=0.195) (Table 3, Fig 4). Not a significant trend was 
noted between the year of diagnosis and the likelihood of genetic counseling (p= 0.196) (Fig 5a, 
Fib 5b). The time between diagnosis and the first visit to genetic counseling decreased over the 
years (Fig 7). A trend was noted, but it was not statistically significant, likely due to the few 
number of patients seen over the years. 
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Young female breast cancer population 
A total of 521 eligible patients were identified from the PMH cancer registry, and eight were 
excluded based on their diagnoses, making initial number of patients 529. Excluded pathology 
included angiosarcoma, lymphoma, hemangiosarcoma, peripheral nerve sheath tumour, and 
phyllodes tumour. 169 received genetic counseling at FBOCC and 146 were seen at a different 
genetic counseling clinic; 313 (60%) patients were tested through Mount Sinai Hospital 
Pathology Lab (Table 9, Table 10). Demographic information for those individuals counselled at 
FBOCC is included in Table 10. Six patients out of 169 (3.55%) who attended genetic 
counseling at FBOCC declined genetic testing. Age at diagnosis ranged from 16 to 35, with the 
mean age being 31.5. There was a correlation between age and likelihood of genetic testing 
(p=0.017) (Table 14). However, there was no a correlation between pathogenic variant finding 
and a family history of breast (p=0.071) (Table 15). Family history information could not be 
obtained for patients who were not seen for genetic counseling at FBOCC. In total, 163 of 169 
(96.4%) patients who had genetic counseling at FBOCC pursued genetic testing, 39 of 163 
(25%) patients had a BRCA1 or BRCA2 pathogenic mutation; three additional patients were 
identified to have pathogenic mutations in other genes (PALB2, TP53 or STK11) (Table 14, Fig 
11). Most mutation carriers had a family history of cancer, not necessarily breast or ovarian. One 
patient with STK11 mutation had no family history of cancer.  
 
Univariate analysis showed the proportion of women opting for genetic testing increasing with 
older ages at diagnosis such that age at diagnosis was a significant predictor of attending genetic 
counseling or having genetic testing (p = 0.017) (Table 16). Results from linear regression 
analysis showed that for each year increase in date of diagnosis, there was an increase in the 
number of genetic testing, with a positive correlation of 1.52 (Table 13, p=4.57E-06). There was 
a positive trend between the year of diagnosis and the time to genetic counseling for young 
female patients (Fig 9, Table 13, p=4.57E-06).  
 
Discussion 
Current guidelines for referral to genetic counselling state that any women diagnosed with breast 
cancer at age 35 or under or any male breast cancer diagnosed at any age should be initiated, 
regardless of family history of breast and/or ovarian cancer, as these groups are eligible for 
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genetic testing. Mutation status for the young patients is helpful in determining clinical 
management. Risk of second breast cancer or other primary cancer might be of concern. Cascade 
testing for family members could also be offered to identify other relatives at risk, which could 
then facilitate increased screening or prevention for those family members. Despite clear 
guidelines for genetic counseling and genetic testing among these patient groups, uptake of 
genetic testing is lagging. In male breast cancer patients, only 44% pursued genetic testing. 
Among young female breast cancer patients, a greater proportion (60%) opted for genetic testing 
(Fig 8), yet there remain many members of both groups who might benefit from genetic testing 
but were not seen for genetic counseling (56% of male breast cancer patients and 60% of young 
female breast cancer patients) and subsequently were not offered genetic testing. This suggests 
barriers and/or resistance to the access to genetic counseling. Identifying these barriers and 
developing strategies to ameliorate them are the next step in increasing identification of those 
individuals and families at high risk to develop cancer.  
 
One potential reason for low numbers of patients seen for genetic counseling is a lack of patient 
awareness for genetic counseling or testing. 96.4% of female patients who attended genetic 
counseling proceeded with genetic testing; this indicates that there is a high interest among those 
who are aware of genetic testing as an option. Thus, it suggests that the low numbers of genetic 
testing do not appear to be due to low patient interest as such a high proportion of those who 
have counseling pursued testing. Perhaps it is more likely that low numbers of genetic testing are 
due to lack of awareness about or interest in genetic counseling.  
 
Additionally, studies have shown that patients are more likely proceed with genetic testing if it 
could influence their treatment or benefit their family members (Lacour et al., 2008; Meiser et 
al., 2018), both topics which would likely be reviewed during a genetic counseling session. With 
a high interest in testing following proper education during genetic counseling, it seems likely 
that patients are unaware of the availability of genetic counseling and testing. Increasing 
awareness among eligible patients should therefore be promoted and prioritized by the providers.  
 
Physicians caring for men or young women with breast cancer should be aware of the 
recommended referral practices. While studies have indicated that pathogenic mutation rate 
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among breast cancer patients is between 10-15%, this incidence rate is likely higher among in 
women in younger age at diagnosis, as indicated in the findings of the present study. National 
Comprehensive Cancer Network (NCCN) guideline recommend that any female diagnosed with 
breast cancer at age 50 or younger be offered genetic counseling. In Ontario, the age at diagnosis 
threshold is lower at age 35. Our study demonstrates that the positive mutation rate was 
relatively high at 25% (Figure 11). This confirms usefulness of the current criteria and suggests 
Ontario Ministry of Health (MOH) could consider increasing this lower age limit for genetic 
testing eligibility to capture more patients who might be pathogenic mutation carriers. 
 
Another factor in reduced genetic test uptake rate, especially for male breast cancer patients, 
might be social stigma surrounding a diagnosis of a cancer type typically found in females. A 
study by Li et al. (2018) has shown that breast cancer diagnosis in male patients negatively 
impacts self-efficacy, as well as the relationship between physician and patient (Li et al., 2018). 
Another study by France et al. (2000) demonstrated that psychological and social factors play 
significant roles in male breast cancer patients, delaying their care and management (France et 
al., 2000). Similar factors might be influencing reduced referral for genetic counseling and 
testing in our male patient population.  
 
In addition to age at diagnosis, year of diagnosis also was shown to be a significant predictor of 
referral to genetic counseling for both men and women. This correlation is likely due to 
increasing physician awareness of the availability of genetic testing. In support of this is our 
observation that patients with a more recent diagnosis of breast cancer had a significant shorter 
period of time between diagnosis and genetic counseling. From this, we can further conclude that 
there has been an increase in the number of patients seen at genetic counseling clinics, and for 
those who are seen at genetics, they are being referred earlier in their cancer journey.  
 
Of the female patients who were referred to genetic counseling, 59% reported a family history of 
breast cancer; 50% of male patients reported a positive family history of breast cancer. Studies 
have shown that only 13-16% of all women with breast cancer have a positive family history 
(Cancer, 2001). This suggests that there may be a tendency for physicians to only refer patients 
to genetic counseling when there is also a family history of cancer, even though characteristics of 
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the personal diagnosis may be sufficient to meet eligibility criteria for a referral. Another 
possible explanation is the greater incidence of hereditary predisposition among young women 
with breast cancer (25% of our study population). 
 
A limitation to this study is incomplete patient records available for review. It was assumed that 
patients diagnosed or treated at PMH would be seen for genetic counseling at the FBOCC. 
However, some chose to pursue genetic counseling at another hospital, yet testing was performed 
through MSH pathology lab. For those who had genetic counseling elsewhere, we were unable to 
access information such as family history, ethnicity, referral history or wait time. Additionally, 
there was missing information on patients who pursued genetic counseling elsewhere but 
declined testing. While we set out to investigate the pathology information on both male and 
female patients, we were unable to obtain complete set of data on this aspect of the study. If they 
received care elsewhere, we were unable to access detailed pathology information including 
tumour receptor status. 
 
In conclusion, despite the Ministry of Health guidelines that women diagnosed with breast 
cancer at age 35 or younger, or any men diagnosed with breast cancer at any age should be 
referred for genetic counseling irrespective of family history, this practice is not occurring at 
optimal rates at our centre. As the result, the number and proportion of men or young women 
with breast cancer seen for genetic counseling is lower than expected and does not allow for 
maximal identification of individuals who might benefit from genetic testing.  Additionally there 
is evidence that those without any family history of cancer might be disproportionally affected 
by the low rate of referral for genetic counseling. A significant proportion of men and women 
with breast cancer who are eligible for genetic testing are missing the opportunity to have testing, 
the results of which might impact their management and ultimate outcomes, as well as the health 
and wellbeing of family members. Given the current understanding of the benefits of testing, it is 
important that efforts to improve referral rates are established and enacted. Educational 
initiatives for both physicians and patients should be implemented, and the referral rates should 
be continually monitored to ensure improvement, and additional research should be done to 
identify and address other barriers. Additionally, we recommend that practice guidelines review 
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evidence of mutation rates in young breast cancer patients and consider increasing the age at 
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total number of patients 101
genetic testing provided 44












genetic testing uptake among male 
breast cancer patients
Table 1
Figure  1. Despite the genetic testing 
eligibility guidelines established by the 
Ministry of Health, only 44% of male breast 
cancer patients received genetic testing 
between 2000-2016.
Figure  2. Pathogenic mutation rate in 
































Age Group Distribution of Male Breast Cancer Dx 
Table 2
Figure 3. Age distribution of male breast cancer 
diagnosis, N for each age group is indicated at the 
right end of each bar. N=101
2


























% genetic testing uptake in male breast cancer
Table 3
Figure 4. percentage of male patients receiving genetic testing by 
age at the time of breast cancer diagnosis. N=101
3
Figure 5a. percentage of male patients who had genetic testing 
by year of diagnosis. N=101
4












































2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Number of male breast cancer patients seen for genetic testing 
over the years
Figure 5b. There is no correlation between the number of male breast cancer seen for genetic testing over 
the years. P= 0.196.
p= 0.196, not 
significant



























mean age at dx 63.38613861
mean age, tested group 60.5 53-85 (age range)
mean age, not tested 65.6 39-88 (age range)
P=0.195, not 
significant











Table 7. Most male breast cancer cases in our 
cohort is luminal A type, ER+ PR+ Her2-.
28 seen at FBOCC
6
year 2000 2002 2004 2005 2006 2008 2009 2010 2011 2012 2013 2014 2015
number 
of 
months 164 88 125 110 38 4 6 8 15 33 5 0.27 4
34 11 7 19 7 11
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MONTHS BETWEEN DX AND FIRST GC VISIT-MALE
Table 8
Figure 6. Scatter plot demonstrating time in months between diagnosis of breast cancer and 
first genetic counseling visit by the year of diagnosis. N =27. 
7
Number of months between diagnosis and genetic 
counseling
Figure 7. Modified boxplot demonstrating time in months between diagnosis of ovarian 
cancer and first genetic counseling visit by the year of diagnosis. N =27. Median values are 




Genetic testing uptake among female under 35
N=521
Yes to Genetic Testing 313
No to Genetic testing 208
total 521
Young Female data
progeny data progeny +MSH
tested through 
MSH - 146
African 3 African 3
AJ 14 AJ 14
Asian 29 Asian 29
Caucasian 78 Caucasian 78
East Indian 11 East Indian 11
Hispanic 3 Hispanic 3
Middle Eastern 8 Middle Eastern 8
West Indies 6 West Indies 6
Mixed 15 Mixed 15
Unknown 2 Unknown 146
total 169 total 315
Table 9.
Figure 8. Ministry of Ontario’s genetic testing eligibility criteria  encourages all 
women diagnosed with breast cancer at age 35 or younger get tested. Yet 
genetic testing uptake rate between 2000—2016 is only about 60%.
Table 10.
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dx and gc 156 84 6 115 84 60 12 6 3 15 3 1 1 7 1 5 2
156 39 120 15 58 19 146 98 36 4 0 9 0 4 4 22 3
136 13 158 108 8 114 19 42 1 2 2 1 2 2 1
29 12 35 14 10 22 2 4 2 3 3 5 2 2 1
14 37 12 27 14 2 66 2 6 4 2
140 6 13 47 7 10 1 6 2 1 4
75 18 65 36 2 0 1 3 3 2
130 9 0 6 36 3 0 2 0 5
4 3 3 4 1 7 0 1 3 2
8 2 1 58 1 1 13 3 1
2 1 4 8 1 8 1 2
9 2 4 1 1 4 1
1 3 1 9 5
8 1 4 2
3 1
Table 11
Figure 9. Modified box plot demonstrating time in months between diagnosis of breast cancer 
and first genetic counseling visit by year of diagnosis. Median values are indicated as thick 
horizontal lines and the quartile ranges as upper and lower edges. Outliers are shown as 



























2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016




























df SS MS F Significance F
Regression 1 942.156863 942.156863 48.4440113 4.57484E-06




Error t Stat P-value Lower 95% Upper 95% Lower 95.0% Upper 95.0%
Intercept -3033.0196 438.40599 -6.9182896 4.9078E-06 -3967.459855 -2098.5794 -3967.4599 -2098.5794
year 1.51960784 0.21832903 6.96017322 4.5748E-06 1.054250539 1.98496515 1.05425054 1.98496515
Table 12. Summary of the 
number of young female 
patients seen for genetic testing 
over the years.
Table 13. Linear regression data between number of young female 
patients seen over the years. There is a positive correlation between the 
number and the years (coeffeicint of 1.52), with a p value of 4.57E-06. 
Figure 10. 
There is an 

































Table 14. Young female
genetic testing results
Figure 11. Despite the conventional understanding that only 10-15% of 
breast cancer cases are hereditary, in the younger population, there 
was a greater incidence of pathogenic mutations at 25%. 
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Table 15. Correlation between pathogenic variant findings and family history of breast cancer
ACTUAL PREDICTED
Negative Positive Totals Negative Positive Totals Chi-Square
Family Hx br 63 30 93 68.0 25.0 93 0.070697983 declined or no info
No Family Hx br 54 13 67 49.0 18.0 67 9
117 43 160 117 43 160
There is no significant correlation between positive genetic test result and presence of breast cancer 
family history. P= 0.071.
P=0.017
Correlation between genetic testing (gt) and age at diagnosis
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Table 16
